TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company developing novel small molecule drugs to treat cancer, closed a $23M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, The Vertical Group and Amgen Ventures.